Compare TYRA & JJSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | JJSF |
|---|---|---|
| Founded | 2018 | 1971 |
| Country | United States | United States |
| Employees | N/A | 1800 |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2021 | 1995 |
| Metric | TYRA | JJSF |
|---|---|---|
| Price | $20.07 | $81.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 3 |
| Target Price | $47.45 | ★ $110.50 |
| AVG Volume (30 Days) | ★ 957.1K | 162.1K |
| Earning Date | 11-04-2026 | 11-16-2026 |
| Dividend Yield | N/A | ★ 3.92% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.99 |
| Revenue | N/A | ★ $1,022,038,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.98 |
| P/E Ratio | ★ N/A | $41.05 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.35 | $68.87 |
| 52 Week High | $40.65 | $98.63 |
| Indicator | TYRA | JJSF |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 55.99 |
| Support Level | $18.66 | $79.72 |
| Resistance Level | $27.00 | $82.03 |
| Average True Range (ATR) | 1.12 | 1.68 |
| MACD | -0.14 | 0.65 |
| Stochastic Oscillator | 7.94 | 79.67 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.